

13th
International
Conference
on Reproduction,
Pregnancy
and Rheumatic
diseases

Vienna, Austria
8-10 May 2025

PRELIMINARY PROGRAMME



ENDORSEMENTS

This conference is endorsed by



WELCOME MESSAGE

Welcome back to the RheumaPreg Conference 2025, set against the backdrop of Vienna, the enchanting home of Mozart and Freud!

As we assemble for this year's conference, we embark on a comprehensive exploration of the intricate relationship between rheumatic diseases and pregnancy, addressing key challenges and breakthroughs in our evolving understanding. We would like to exchange experiences, catch-up on the past two years, enjoy the springtime over a cup of Viennese coffee with old friends and new colleagues.

We are committed to interdisciplinarity. For this reason, panel discussions and curbside consultations will involve esteemed experts from the fields of rheumatology, obstetrics, haemostasiology, intensive care medicine and neonatology, pathology and patient representatives.

Among others, updates on evolving guidelines, medication use, counselling, use of assisted reproduction techniques, management during and after pregnancy and acute situations will be elaborated and presented together with clinical cases. We will dig down to the root of common problems during pregnancy and learn about immunology and placental pathologies related to rheumatic diseases and complications.

Furthermore, the conference will provide a platform for revisiting teratogenicity of therapies, scrutinizing the latest evidence to ensure an updated perspective on treatment safety during pregnancy, breastfeeding and data about long-term follow up of the children.

Lastly, we will revisit the progress of the existing registries and address the problems associated with the lack of standardized definitions, particularly delving into the complexity of terms like "adverse obstetric outcome" or "disease activity" which pose obstacles in comparing results.

We would like to thank the RheumaPreg 2025 Congress Committee, the organizational team and all members of the RheumaPreg community for their commitment and efforts in shaping this congress. Additionally, we wish to express gratitude to all delegates who will attend and contribute to the Congress in 2025 in Vienna.

Join us in this intellectual journey, where we will not only revisit established knowledge but also navigate the complexities of interdisciplinary management, pose new questions and address the latest developments.

Welcome back to RheumaPreg Vienna 2025 - Together, let's shape the future of rheumatology in pregnancy!

Assoc. Prof. Klara Rosta, PhD
Chair - Obstetrics/Gynecology



Dr. Antonia Mazzucato-Puchner
Chair - Rheumatology



CONGRESS COMMITTEE

CONGRESS CHAIRS

Klara Rosta | Austria

Antonia Mazzucato-Puchner | Austria

LOCAL SCIENTIFIC COMMITTEE

Julia Binder | Austria

Christine Duftner | Austria

Ruth Fritsch-Storck | Austria

Karoline I. Mayer-Pickel | Austria

Judith Sautner | Austria

PAST ORGANIZERS

Catherine Nelson-Piercy | UK

Angela Tincani | Italy

Laura Andreoli | Italy

FACULTY

Silvia Aguilera | Spain

Bonnie Bermas | USA

Mehret Birru Talabi | USA

Irene E.M. Bultink | The Netherlands

Jill Buyon | USA

Christina Chambers | USA

Megan Clowse | USA

Nathalie Costedoat-Chalumeau | France

Elisabeth D'Costa | Austria

Corinne De Vries | The Netherlands

Radboud J.E.M. Dolhain | The Netherlands

Anne Drapkin Lyerly | USA

Oseme Etomi | United Kingdom

Michael Feichtinger | Austria

Frauke Foerger | Switzerland

Ian Giles | United Kingdom

Isabell Haase | Germany



Maria Hoeltzenbein | Germany
Elvis Hysa | Italy
Alexandra Kautzky-Willer | Austria
Herbert Kiss | Austria
Katrín Klebermass-Schrehof | Austria
Antonios Makrygiannakis | Greece
Julian Marschalek | Austria
Yvette Meissner | Germany
Arsene Mekinian | France
Anna Molto | France
Louise Moore | Ireland
Marta Mosca | Italy
Olivia Nonn | Germany
Kazem Nouri | Austria
Monika Ostensen | Norway
Birgit Pfaller-Eiwegger | Austria
Vinod Ravindran | India
Jane Salmon | USA
Lisa Rose Sammaritano | Usa
Karen Schreiber | Denmark
Savino Sciascia | Italy
Elisabeth Seidl-Mlczoch | Austria
Tanja Stamm | Austria
Jojo Steininger | Austria
Meryam Sugulle | Norway
Bettina Toth | Austria
Anne Troldborg | Denmark
Andrea Ulbrich | Austria
Marianne Wallenius | Norway
Lynne Yao | USA

PRELIMINARY PROGRAMME OVERVIEW

Thursday, 8 May 2025 **Room OLYMPIA MANCINI 2**

13:00-13:15	Welcome Message
13:15-14:35	Challenges of fertility in context of rheumatic disease and social changes
14:35-15:55	Under the magnifying glass: the placenta as a cause of various pregnancy pathologies
15:55-16:25	Coffee Break
16:25-17:45	Navigating Pregnancy with SLE: Challenges and Innovations
17:45-19:05	Stay updated: news on reproduction with...
19:05-19:25	Opening Lecture

Friday, 9 May 2025 **Room OLYMPIA MANCINI 2**

08:30-09:30	Inclusion of pregnant people with chronic rheumatological conditions in research and clinical trials: where do we stand?
09:30-10:40	Beyond the clot
10:40-11:10	Coffee Break
11:10-12:10	Curbside Consultation 1 - Neonatal Lupus
12:10-14:10	Lunch break and Poster tour

PRELIMINARY PROGRAMME OVERVIEW

Friday, 9 May 2025 **Room OLYMPIA MANCINI 2**

14:10-15:10	Immunosuppression during pregnancy
15:30-16:30	The hormonal factor in rheumatic diseases
16:30-17:00	Coffee Break
17:00-18:00	Round table: update on the registries

Saturday, 10 May 2025 **Room OLYMPIA MANCINI 2**

08:30-09:30	INDUSTRY-SPONSORED SYMPOSIUM
09:30-10:15	Debate Session: Gynecologist vs Rheumatologist about immuno modulation for recurrent implantation failure and miscarriage
10:15-10:45	Coffee Break
10:45-11:45	Curbside Consultation 2 - Patient perspectives: family planning with rheumatic diseases
11:45-12:55	Long-term post-partum challenges
12:55-13:25	Gender diversity: inclusivity and the importance of language
13:25-13:40	Closing remarks

LEGENDA

CONGRESS SESSIONS AND ORAL PRESENTATIONS

INDUSTRY-SPONSORED SYMPOSIUM

PRELIMINARY PROGRAMME

Thursday, 8 May 2025

- 13:00-13:15** **WELCOME MESSAGE**
*Chairs: K. Rosta (Vienna, Austria),
A. Mazzucato-Puchner (Vienna, Austria),
H. Kiss (Vienna, Austria)*
- 13:15-14:35** **CHALLENGES OF FERTILITY IN CONTEXT OF
RHEUMATIC DISEASE AND SOCIAL CHANGES**
*Chairs: I. Haase (Hamburg, Germany),
K. Nouri (Oberpullendorf, Austria),
V. Ravindran (Calicut, India)*
- 13:15-13:35** **Ovarian reserve: current diagnostic and therapeutic
options**
B. Toth (Innsbruck, Austria)
- 13:35-13:55** **Fertility preservation in rheumatic diseases**
J. Marschalek (Vienna, Austria)
- 13:55-14:15** **How to approach infertility in rheumatic diseases**
K. Rosta (Vienna, Austria)
- 14:15-14:25** **NORMAL FERTILITY IN WOMEN WITH RHEUMATOID
ARTHRITIS AND A WISH TO CONCEIVE WHEN
TREATED ACCORDING TO A T2T-APPROACH
INCLUDING THE USE OF TUMOR NECROSIS
INHIBITORS, AIMED AT REMISSION**
C.H. Quaak, E. Röder, H.M. Wintjes,
A.J. Van Steensel-Boon, A.G.M.G. Mulders,
L.J.C. Kranenburg - Van Koppen, R.J.E.M. Dolhain
(Rotterdam, The Netherlands)

PRELIMINARY PROGRAMME

- 14:25-14:35 **SAFETY AND EFFICACY OF ASSISTED REPRODUCTIVE TECHNIQUES IN PREGNANT WOMEN WITH SYSTEMIC AUTOIMMUNE DISEASES: EXPERIENCE OF TERTIARY CARE CENTERS OF THE NORTH OF ITALY**
V. Canti¹, M.B. Cilona¹, F. Pasi¹, A. Calligaro², F. Ruffilli³, M. Tonello², E. Giacobbe¹, M.C. Gerardi¹, M. Padovan³, V.S. Vanni¹, E. Bizzi¹, E. Papaleo¹, B. Maranini³, M. Govoni³, M. Epis¹, A. Doria², P. Rovere-Querini¹
(¹Milan, Italy; ²Padua, Italy; ³Ferrara, Italy)
- 14:35-15:55 **UNDER THE MAGNIFYING GLASS: THE PLACENTA AS A CAUSE OF VARIOUS PREGNANCY PATHOLOGIES**
*Chairs: J. Binder (Vienna, Austria),
J. Salmon (New York, USA)*
- 14:35-14:55 **Placental pathology in systemic lupus erythematosus pregnancies**
I.E.M. Bultink (Amsterdam, The Netherlands)
- 14:55-15:15 **Placental pathology in preeclampsia: what do we know so far**
O. Nonn (Berlin, Germany)
- 15:15-15:35 **Preeclampsia and fetal growth restriction in rheumatic disease: placenta-mediated conditions with short and long-term health consequences**
M. Sugulle (Oslo, Norway)
- 15:35-15:45 **HISTOPATHOLOGICAL PLACENTAL FINDINGS IN ANTIPHOSPHOLIPID ANTIBODY CARRIERS WITH A FETAL LOSS BEYOND 12 WEEKS OF PREGNANCY**
N. Baños¹, S. Dos Santos Beca¹, A. Peguero¹, M. Borrell¹, A. Castellanos², F. Figueras¹, A. Nadal¹, G. Espinosa¹
(¹Barcelona, Spain; ²Jena, Germany)

PRELIMINARY PROGRAMME

- 15:45-15:55 **ANGIOGENIC MARKERS IN PLACENTAL TISSUE OF AUTOIMMUNE DISEASE PATIENTS**
P. Fuentes-Zacaria¹, A.S. Castellanos Gutierrez¹, N. Baños², F. Figueras², G. Espinosa², E. Schleußner¹, T. Groten¹, D.M. Morales-Prieto¹
(¹Jena, Germany; ²Barcelona, Spain)
- 15:55-16:25 Coffee break
- 16:25-17:45** **NAVIGATING PREGNANCY WITH SLE: CHALLENGES AND INNOVATIONS**
Chairs: E. D'Costa (Innsbruck, Austria), C. Nelson-Piercy (London, UK)
- 16:25-16:45 **How to manage advanced new therapies during pregnancy?**
I. Giles (London, UK)
- 16:45-17:05 **Importance of complement in SLE**
R. Fritsch-Stork (Vienna, Austria)
- 17:05-17:25 **Lupus nephritis and preeclampsia: how to differentiate**
S. Sciascia (Turin, Italy)
- 17:25-17:35 **THE UTILITY OF THE SFLT1: PLGF RATIO TO RULE OUT AND PREDICT PREECLAMPSIA IN WOMEN WITH LUPUS**
M. Clowse, K. Addae-Konadu, J. Federspiel, J. Gilner, E. Kovalik, A. Lucas, L. Neil, C. Sims, A. Snyderman, A. Eudy (Durham, USA)
- 17:35-17:45 **ADVERSE PREGNANCY OUTCOME ASSOCIATIONS AMONG WOMEN PRIOR TO DIAGNOSIS OF SYSTEMIC LUPUS ERYTHEMATOSUS**
J. English, B. Wolf, D. Kamen (Charleston, USA)

PRELIMINARY PROGRAMME

- 17:45-19:05** **STAY UPDATED: NEWS ON REPRODUCTION WITH...**
*Chairs: C. Duftner (Vienna, Austria),
A. Molto (Paris, France)*
- 17:45-18:05 **Inflammatory arthritis**
R. Dolhain (Rotterdam, The Netherlands)
- 18:05-18:25 **Connective tissue disorders**
M. Mosca (Pisa, Italy)
- 18:25-18:45 **Vasculitis**
M. Clowse (Durham, USA)
- 18:45-18:55 **MATERNAL AND NEONATAL OUTCOMES IN WOMEN
WITH SYSTEMIC SCLEROSIS GIVING BIRTH BEFORE
AND/OR AFTER DIAGNOSIS - A SWEDISH
POPULATION-BASED COHORT STUDY**
K. Hellgren¹, I.C. Weng¹, L. Annicchiarico¹, L. Andreoli^{2,3},
O. Stephansson¹, M. Holmqvist¹
(¹Stockholm, Sweden; ²Brescia, Italy; ³Odense,
Denmark)
- 18:55-19:05 **MEN WITH IJD ARE YOUNGER WHEN BECOMING
FATHERS - IS THERE AN ASSOCIATION BETWEEN
ENTERING FATHERHOOD AND DEVELOPING
INFLAMMATORY JOINT DISEASE?**
G.D. Sismo¹, S. Hauge², M. Wallenius³, M.B. Lauvsnes¹,
H.B. Hetland¹, K.Å. Salvesen³, G. Bakland⁴,
A.K.N. Daltveit², B.S. Fevang²
(¹Stavanger, Norway; ²Bergen, Norway; ³Trondheim,
Norway; ⁴Tromsø, Norway)
- 19:05-19:25** **OPENING LECTURE - BEYOND RHEUMATOLOGY:
ETHICAL ISSUES**
*Chairs: K. Rosta (Vienna, Austria),
A. Mazzucato-Puchner,
A. Drapkin Lyerly (Chapel Hill, USA)*

PRELIMINARY PROGRAMME

Friday, 9 May 2025

- 08:30-09:30** **INCLUSION OF PREGNANT PEOPLE WITH CHRONIC CONDITIONS IN RESEARCH AND CLINICAL TRIALS: WHERE DO WE STAND?**
Chair: L. Andreoli (Brescia, Italy)
- 08:30-08:40 **Regulatory framework of data generation in the United States (FDA): status quo and future prospects for the inclusion of pregnant women in clinical trials**
L. Yao (Washington, USA)
- 08:40-08:50 **Regulatory framework of data generation in Europe (EMA): status quo and future prospects for the inclusion of pregnant women in clinical trials**
C. De Vries (Amsterdam, The Netherlands)
- 08:50-09:00 **Obstetric Medicine: practice in an evidence poor zone**
C. Nelson-Piercy (London, UK)
- 09:00-09:30 **Panel discussion: Current challenges in generating research data in pregnant and breastfeeding women with chronic rheumatological diseases**
Discussants:
S. Aguilera (Elche, Spain)
C. De Vries (Amsterdam, The Netherlands)
A. Drapkin Lyerly (Chapel Hill, USA)
C. Nelson-Piercy (London, UK)
K. Rosta (Vienna, Austria)
K. Schreiber (Sonderborg, Denmark)
L. Yao (Washington, USA)
- 09:30-10:40** **BEYOND THE CLOT: CHALLENGES IN OBSTETRIC ANTIPHOSPHOLIPID SYNDROME**
*Chairs: N. Costedoat-Chalumeau (Paris, France),
K.I. Mayer-Pickel (Graz, Austria)*

PRELIMINARY PROGRAMME

- 09:30-09:50 **Implications of new classification criteria of APS - What does it mean for you?**
K.I. Mayer-Pickel (Graz, Austria), A. Tincani (Brescia, Italy)
- 09:50-10:10 **"Quo vadis" obstetric APS**
K. Schreiber (Sønderborg, Denmark)
- 10:10-10:30 **The inhibition of TNF in difficult-to-treat obstetric APS**
J. Salmon (New York, USA)
- 10:30-10:40 **PATIENT PERSPECTIVES ON REFRACTORY SYSTEMIC LUPUS ERYTHEMATOSUS AND/OR ANTIPHOSPHOLIPID SYNDROME DURING PREGNANCY**
J. Kooiman¹, J. van Woerkom², M. Wind³, O. Teng³, T. Lely², J. Pullen², G. Jansen¹, L. Perez¹, R. Dolhain¹, M. Limper²
(¹Rotterdam, The Netherlands; ²Utrecht, The Netherlands; ³Leiden, The Netherlands)
- 10:40-11:10 Coffee break
- 11:10-12:10 **CURBSIDE CONSULTATION 1 - NEONATAL LUPUS**
Chairs: J. Sautner (Vienna, Austria), O. Etomi (London, UK)
- When to treat? And who and how much should we monitor?**
Presenter: A. Troldborg (Aarhus, Denmark)
Discussants: J. Buyon (New York, USA), N. Costedoat-Chalumeau (Paris, France), E. Seidl-Mlczoch (Vienna, Austria)
- 12:10-14:10 Lunch break and Poster tour

PRELIMINARY PROGRAMME

- 14:10-15:10** **IMMUNOSUPPRESSION DURING PREGNANCY**
*Chairs: B. Bermas (Dallas, USA),
A. Mazzucato-Puchner (Vienna, Austria)*
- 14:10-14:30 **2024 Update of EULAR recommendations**
F. Förger (Bern, Switzerland)
- 14:30-14:50 **Biologics during pregnancy**
I. Giles (London, UK)
- 14:50-15:10 **Oops, I am pregnant! Teratogenicity and decision making**
M. Hoeltzenbein (Berlin, Germany)
- 15:10-15:20** **ROTAVIRUS VACCINATION DURING THE FIRST 6 MONTHS OF LIFE IN OFFSPRING EXPOSED TO TUMOUR NECROSIS FACTOR INHIBITORS WAS NOT ASSOCIATED WITH AN INCREASED RISK OF DIARRHEA EVENTS DURING THE FIRST 2 YEARS**
L. Flatman, M.E. Beauchamp, Y. St-Pierre, I. Malhamé, A. Bérard, S. Bernatsky, É. Vinet (Montreal, Canada)
- 15:20-15:30** **THE EFFECT OF BIOLOGIC TREATMENT FOR PSORIATIC ARTHRITIS AND AXIAL SPONDYLOARTHRITIS ON SEMEN PARAMETERS - A LONGITUDINAL STUDY**
A. Polachek, K. Meridor, S. Barda, D. Rosenberg, D. Paran, O. Elkayam (Tel Aviv, Israel)
- 15:30-16:30** **THE HORMONAL FACTOR IN RHEUMATIC DISEASES**
*Chairs: A. Kautzky-Willer (Vienna, Austria),
M. Østensen (Norway)*
- 15:30-15:50 **The influence of hormones on the course of rheumatic diseases**
E. Hysa (Genoa, Italy)

PRELIMINARY PROGRAMME

- 15:50-16:10 **Contraception in rheumatic diseases**
K. Rosta (Vienna, Austria), L. Sammaritano (New York, USA)
- 16:10-16:30 **Menopause - Hormonal therapy and alternatives in rheumatic diseases**
B. Bermas (Dallas, USA)
- 16:30-17:00 Coffee break
- 17:00-18:00 ROUND TABLE: UPDATE ON THE REGISTRIES - PROSPECTIVE COHORTS - TRIALS IN PREGNANCY**
Chairs: C. Chambers (San Diego, USA), T. Stamm (Vienna, Austria)
L. Andreoli (Brescia, Italy)
M. Clowse (Durham, USA)
N. Costedoat-Chalumeau (Paris, France)
F. Förger (Bern, Switzerland)
A. Mazzucato-Puchner (Vienna, Austria)
Y. Meissner (Berlin, Germany)
A. Molto (Paris, France)
K. Schreiber (Sønderborg, Denmark)
A. Tincani (Brescia, Italy)
M. Wallenius (Trondheim, Norway)

PRELIMINARY PROGRAMME

Saturday, 10 May 2025

08:30-09:30 INDUSTRY-SPONSORED SYMPOSIUM

09:30-10:15 DEBATE SESSION: GYNECOLOGIST VS RHEUMATOLOGIST ABOUT IMMUNOMODULATION FOR RECURRENT IMPLANTATION FAILURE AND MISCARRAGE

*Chairs: M. Feichtinger (Vienna, Austria),
K. Nouri (Oberpullendorf, Vienna)
A. Makrigiannakis (Crete, Greece)
vs A. Mekinian (Paris, France)*

10:15-10:45 Coffee break

10:45-11:45 CURBSIDE CONSULTATION 2 - PATIENT PERSPECTIVES: FAMILY PLANNING WITH RHEUMATIC DISEASES

*Chairs: M. Clowse (Durham, USA),
M. Østensen (Norway)*

Pre pregnancy counselling for complex scleroderma

Presenter: C. Nelson-Piercy (London, UK)

Discussants:

S. Aguilera (Elche, Spain)

K. Klebermass-Schrehof (Vienna, Austria)

L. Moore (Dublin, Ireland)

J. Sautner (Vienna, Austria)

11:45-12:55 LONG-TERM POST-PARTUM CHALLENGES

*Chair: M. Birru Talabi (Pittsburgh, USA),
A. Ulbrich (Vienna, Austria)*

11:45-12:05

Long-term maternal cardiovascular risk: bridging risk assessment and postpartum care

B. Pfaller-Eiwegger (St. Pölten, Austria)

PRELIMINARY PROGRAMME

- 12:05-12:25 **Lactation with rheumatic diseases: a guide for counselling**
M. Birru Talabi (Pittsburgh, USA)
- 12:25-12:45 **Long-term follow up of children**
L. Andreoli (Brescia, Italy)
- 12:45-12:55 **IMMUNE SYSTEM PROFILE OF NEWBORNS BORN TO MOTHERS TREATED WITH TNF INHIBITORS THROUGH PREGNANCY**
Y. Luo¹, A. Freixedas¹, N. Baños¹, D. Acevedo¹, E. Quesada¹, A. Pluma¹, R. Castellanos-Moreira¹, S. Rodríguez-García¹, A. Deyà¹, A. García-García¹, E. Moreno¹, M. Torres¹, M. Casellas¹, D. Grados², M. Juan¹, A. Esteve-Solé¹, L. Alsina¹
(¹Barcelona, Spain; ²Igualada, Spain)
- 12:55-13:25 GENDER DIVERSITY: INCLUSIVITY AND THE IMPORTANCE OF LANGUAGE**
Chair: A. Kautzky-Willer (Vienna, Austria)
J. Steininger (Vienna, Austria)
- 13:25-13:40 CLOSING REMARKS**
K. Rosta (Vienna, Austria),
A. Mazzucato-Puchner (Vienna, Austria)

SCIENTIFIC INFORMATION

Abstract Submission

Abstracts can only be submitted through the Congress website and no later than **December 15th, 2024**. Abstracts received by e-mail will not be considered. Should you have any problems in submitting an abstract online, please contact the Organizing Secretariat at rheumapreg2025@aimgroup.eu.

Abstract Notification

Once the abstract is submitted, a confirmation email will be sent to the registered author's e-mail address provided in the 'Personal Details' section.

Notification of abstract acceptance will be sent via email by January 17th, 2025.

The registered author is responsible for sharing the outcome of the abstract examination and any other related information with their co-authors.

Please note that the presenting author of the accepted abstract must be registered to attend the Congress.

Abstract Requirements

When you submit the abstract, please indicate your preferred method of presentation (poster or oral communication) and select the category that best describes the content of your paper.

Topics:

- Immunosuppressive therapy of rheumatic diseases during pregnancy and lactation
- Management of Rheumatoid Arthritis, Psoriatic Arthritis, Axial Spondyloarthritis, and Juvenile Idiopathic Arthritis during Pregnancy
- Pregnancy with Lupus
- Antiphospholipid Syndrome: from understanding to evolving management
- Myositis, Scleroderma, Sjögren's and Vasculitis in pregnancy
- Revisiting Osteoporosis in reproductive years

- Recurrent Pregnancy loss and the role of IVIG therapy: myth and evidence
- From placenta pathology to adverse obstetric outcome: mechanisms and management (Preeclampsia, FGR, Placental insufficiency)
- Challenges of fertility in context of rheumatic disease and social changes
- Artificial reproductive techniques and the role of fertility preservation in rheumatic diseases
- Update on the registries
- Gender medicine
- Navigating Teratogenic Terrain: contraception and management of unintended pregnancy
- Patient perspectives: family planning with rheumatic diseases, the essential role of teamwork
- Paternal rheumatic disease and medication-influence on family planning
- Supporting new mothers with rheumatic diseases: post-partum challenges
- Long-term follow up of children

Information For Presenters

Each corresponding Author (submitter) can send limitless abstracts. Each accepted abstract has to be presented by a different Presenting Author.

In order to attend the Congress, the Presenting Author of the accepted abstract must be registered.

Oral Presentations

The selected presenting authors are requested to upload their presentation (landscape format 16:9) on a USB drive or laptop and deliver it to the slide center room at least one hour before the beginning of the session.

Posters

All posters must have maximum dimensions of 70 x 100 cm (portrait format).

Please note that poster boards will be set up in a reserved area of the Congress venue and must remain up throughout the Congress, so that participants will be able to view them at their convenience.

Curbside Consultations

These sessions encourage a spontaneous discussion of a difficult clinical case. The case is presented by a speaker who raises a few key questions. The experts give their opinion on the best diagnosis/treatment options and discuss the case among themselves as physicians often do in their daily practice (without any slides).

The case is not previously known by any of the discussants. The speaker's role is to ensure a lively conversation and cover the various approaches, as well as to involve the audience in the conversation.

The Debate Session

The purpose of the debate is to have an intense discussion on some of the most burning controversies related to a specific topic. The two sides of the debate will be defended by two leading experts in the field, and the discussion will be controlled by a moderator whose role is to ensure that all aspects of the debate are duly discussed, as well as to involve the audience in the conversation.

EACCME/UEMS Credits

An application will be submitted to the EACCME® for CME accreditation of this event

CME Provider - AIM Education - Provider n. 93

 AIM EDUCATION

Via E. Forlanini 23

20134 Milan, Italy

Tel. +39 02 56601.1

cme@aimgroup.eu

www.aimeducation.it

GENERAL INFORMATION

Congress Venue



Austria Trend Hotel Savoyen Vienna

Rennweg 16
1030 Wien, Austria

How to reach the venue

Located in the heart of the embassy district, close to the Belvedere Palace and Botanical Gardens, the Austria Trend Hotel Savoyen is easily reachable by any means of transportation.

By flight

Vienna Airport has good connections to the public transport network. The congress venue can be reached quickly by train, bus or cab.

From Vienna Airport Train Station take the REX7 towards Wien Floridsdorf Bahnhof and get off at Wien Rennweg. Walk for about 3 minutes to reach the venue. The whole route takes about 20 minutes.

As an alternative, from Vienna Airport Train Station it's also possible to take the express train S7 towards Laa/Thaya Bahnhof and get off at Wien Rennweg. Walk for about 3 minutes to reach the venue.

Other options may be available depending on the time of departure. For detailed timetable information, please visit the website at www.oebb.at

Taxis are also always available outside the airport, with a fixed fare of 42 € (Taxi 40100, 60160) for a maximum of 4 passengers.

Ride-sharing services such as Uber and Bolt are also good alternatives.

By train



The congress venue is located at a 3-minute distance from the train station Wien Rennweg, and at a 19-minute walking distance from Wien Hauptbahnhof or Vienna Central Station, which is the main railway station in Vienna, located in the Favoriten district.

From the Central Station it's also possible to take a train towards Bruno-Marek-Allee and get off at Wien Rennweg. For detailed timetable information, please visit the website at www.oebb.at

By car



Westautobahn (A1) - towards the centre of Vienna as far as Karlsplatz - continue straight to Schwarzenbergplatz - cross this square and make a right onto Rennweg.

Südbahnhof (A2) - taking the exit for the Vienna city centre - keep straight on Triester Strasse until you reach Matzleinsdorfer Platz - take the right lane onto Wiedner Hauptstrasse and continue until you reach Paulaner Gasse, where you will take a right - continue to the traffic light - make a left onto Favoriten Strasse - the right lane will take you to Schwarzenbergplatz - cross this square and make a right onto Rennweg.

Ostautobahn (A4) - exiting for the centre of Vienna - along Schüttelstrasse as far as Urania building / Aspernbrücke bridge - make a left across Aspernbrücke bridge and continue straight along Stubenring - keep on Ringstrasse until you reach Schwarzenbergplatz - turn left and cross the square onto Rennweg.

Parking facilities



There is a garage directly in the hotel building.

Garage fee: € 18 per day.

Accommodation



The Organizing Secretariat has reserved a limited number of rooms for the attendees at the Lindner Hotel Vienna Am Belvedere (Rennweg 12 - 1030 Wien, Austria), located a few steps away from the congress venue.

These rooms are available for reservation in a limited number. We highly recommend taking advantage of this opportunity and book your accommodation as soon as possible.

The Lindner Hotel Vienna Am Belvedere is a top-rated hotel located in the heart of the city, offering easy access to the RheumaPreg conference and other major attractions.

Please note that the rooms are subject to availability and the deadline for booking is 31 January 2025.

VISA



All non-Austrian nationals entering Austria must provide valid travel documentation. Delegates who hold neither an EU passport nor a Schengen visa should check as soon as possible the Austrian Ministry of Foreign Affairs' website to see if they require a visa to enter the country.

Visa regulations depend on your nationality and country of origin. For the most updated information regarding visa requirements, we do suggest you contact your local consulate for full and official instructions on the specific visa regulations and application procedures that apply to you.

If a visa is required, delegates should apply to the Austrian Diplomatic and Consular Representations in their country of residence with the documents outlined on the Ministry of Foreign Affairs' website. Invitation letters to the conference may be downloaded online through the registration area of our website.

Please Note: Visa applications may take several months. Therefore, we recommend checking all the necessary requirements and procedures well ahead of time.

Visa application fees vary. Please contact the embassy or consulate to enquire about costs.

Presentation of the requested documentation does not guarantee that the visa will be issued.

AIM Group International will be glad to assist you if you need any other written invitation or other document to support your visa application at the following e-mail address: visa@aimgroup.eu

Invitation Letter

The official invitation letter to be included in your application to enter Austria can be downloaded through the registration page.

If you have not submitted your personal data yet, click on "time user" and fill in the form with your personal data. Once you have completed the form, click on "Invitation Letter (VISA)" on the left side menu.

If you have already submitted your personal data, just log in (using your User ID and Password) and click on "Edit your personal data" to insert the passport details. Then, click on "Invitation Letter (VISA)" from the left side menu.

The Invitation Letter will not be legally or financially binding on the organizing secretariat. Expenses related to the conference shall be borne by delegates themselves.

KEY DATES TO REMEMBER

Abstract submission deadline:	December 15th, 2024
Abstract notification:	January 17th, 2025
Early registration deadline:	January 31st, 2025
Regular registration deadline:	April 24th, 2025

Organizing Secretariat



AIM Group International - Milan Office
Viale Enrico Forlanini 23 - 20134 Milan, Italy
Ph. +39 02 566011
rheumapreg2025@aimgroup.eu

Secretariat and Registration Desk

The on-site registration desks will be open during the following days:

- Thursday, 8 May 2025 11:30 - 19:30
- Friday, 9 May 2025 07:45 - 18:30
- Saturday, 10 May 2025 08:00 - 13:40

Admission

All participants are kindly requested to wear their badge during all congress activities. The badge will allow you to access the scientific sessions, the exhibition area, coffee breaks and lunch.

Language

The official language is English. No simultaneous translation will be provided.

Certificate of Attendance

Participants will be able to download and print the Certificate of Attendance upon completion of the online evaluation form they will receive by email at the end of the Congress.

Registration

Registration Fees (all fees are 20% VAT included)

	EARLY REGISTRATION FEES by January 31 st , 2025	REGULAR REGISTRATION FEES by April 24 th , 2025	LATE REGISTRATION FEES from April 25 th , 2025 and on-site
Delegate	€ 350,00	€ 420,00	€ 500,00
Trainees, Students * and Health Professionals **	€ 150,00	€ 180,00	€ 200,00
Developing Countries ***		€ 200,00	

* In order to benefit from the special fee, a submission of your status confirmation must be uploaded online during the registration process (i.e. approval letter signed by the Head of Department or copy of your status ID).

** Nurses, physiotherapists, occupational therapists and other nearby allied health professionals. A letter of confirmation of your status from the Head of Unit or Institute must accompany and uploaded in the online registration.

*** Lower and Middle Country classification as listed and defined according to the World Bank website.

The delegate fee includes:

- Admission to the scientific sessions
- Congress bag holding all the meeting materials
- Certificate of attendance
- Access to the poster area
- Coffee breaks and lunch, according to the programme

Payment

- **by Credit Card**

All major credit cards are accepted (VISA, Mastercard/Eurocard, American Express).

- **by Bank Transfer**

Beneficiary: AIM ITALY

Bank: Intesa San Paolo, Agenzia n. 6 - Viale Coni Zugna 62, 20144 Milano

IBAN:IT57D0306909457100000005623

BIC: BCITITMM

The payment transfer form should clearly state the name(s) of the delegate(s) and of the event "RheumaPreg 2025".

Registration will be considered confirmed when the payment is received.

Name Changes

After 8 April 2025, sponsors who wish to make name changes will be charged of a handling fee of € 50,00 (VAT 20% included) per name change. A new registration form for each replacement participant will be required before the name change can be processed. Individuals may make name changes only in exceptional cases.

Cancellation Policy

Notification of cancellation must be sent in writing to the organizing secretariat (rheumapreg2025@aimgroup.eu).

Cancellations will be accepted until 8 April 2025, with a refund of all prepaid fees except for a 30% administration charge. No refunds will be made for cancellations received after this date.

Unexpected cancellation of the event or impossibility to hold it

In the unlikely case that the 13th RheumaPreg Conference 2025 cannot be held in whole or in part due to any event beyond the Organisers' control or force majeure (such as riot, fire, explosion, accident, flood, earthquake, sabotage, strikes, acts of any government, etc) the Congress Organisers cannot be held liable for any damage, cost, or loss incurred, such as registration fee, transportation and accommodation costs, or any other direct or indirect loss or consequential damage.